期刊
CANCER LETTERS
卷 342, 期 2, 页码 264-274出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.12.026
关键词
Epigenetic-based biomarkers; Genitourinary cancer; DNA methylation; Histone modifications; microRNAs
类别
资金
- European Community's Seventh Framework Programme [FP7-HEALTH-F5-2009-241783]
- Liga Portuguesa Contra o Cancro - Nucleo Regional do Norte
Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations in the assessment of prognosis in an individual basis. Herein, we focus on the development of epigenetic-based GU cancer biomarkers, which have emerged from exploratory studies in recent years and that hold the promise to revolutionize the clinical management of GU cancer patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据